Advanced search
Start date
(Reference retrieved automatically from Web of Science through information on FAPESP grant and its corresponding number as mentioned in the publication by the authors.)

The CCR5 Delta 32 Polymorphism in Brazilian Patients with Sickle Cell Disease

Full text
Show less -
Lopes, Mariana Pezzute [1] ; Nunes Santos, Magnun Nueldo [1] ; Faber, Eliel Wagner [1] ; Cavalcanti Bezerra, Marcos Andre [2] ; Domingues Hatzlhofer, Betania Lucena [2] ; Albuquerque, Dulcineia Martins [3] ; Zaccariotto, Tania Regina [1] ; Ribeiro, Daniela Maria [1] ; Araujo, Aderson da Silva [2] ; Costa, Fernando Ferreira [3] ; Sonati, Maria de Fatima [1]
Total Authors: 11
[1] State Univ Campinas UNICAMP, Sch Med Sci, Dept Clin Pathol, BR-13083970 Campinas, SP - Brazil
[2] HEMOPE Fdn, Pernambuco Hematol & Hemotherapy Ctr, BR-52011900 Recife, PE - Brazil
[3] Univ Estadual Campinas, Hematol & Hemotherapy Ctr, BR-13083878 Campinas, SP - Brazil
Total Affiliations: 3
Document type: Journal article
Source: DISEASE MARKERS; 2014.
Web of Science Citations: 3

Background. Previous studies on the role of inflammation in the pathophysiology of sickle cell disease (SCD) suggested that the CCR5 Delta 32 allele, which is responsible for the production of truncated C-C chemokine receptor type 5 (CCR5), could confer a selective advantage on patients with SCD because it leads to a less efficient Th1 response. We determined the frequency of the CCR5 Delta 32 polymorphism in 795 Afro-Brazilian SCD patients followed up at the Pernambuco Hematology and Hemotherapy Center, in Northeastern Brazil, divided into a pediatric group (3 months-17 years, n = 483) and an adult group (18-70 years, n = 312). The adult patients were also compared to a healthy control group (blood donors, 18-61 years, n = 247). Methods. The CCR5/CCR5 Delta 32 polymorphism was determined by allele-specific PCR. Results. No homozygous patient for the CCR5 Delta 32 allele was detected. The frequency of heterozygotes in the study population (patients and controls) was 5.8%, in the total SCD patients 5.1%, in the children 5.4%, in the adults with SCD 4.8%, and in the adult controls 8.1%. These differences did not reach statistical significance. Conclusions. Our findings failed to demonstrate an important role of the CCR5 Delta 32 allele in the population sample studied here. (AU)

FAPESP's process: 11/02622-3 - Inflammatory aspects versus haptoglobin and hemopexin genotypes and presence of the ccr5d32 polymorphism in sickle cell anemia patients
Grantee:Maria de Fatima Sonati
Support type: Regular Research Grants
FAPESP's process: 08/57441-0 - Clinical, cellular and molecular alterations in hemoglobinopathies and other hereditary hemolytic anemias
Grantee:Fernando Ferreira Costa
Support type: Research Projects - Thematic Grants